BTIG Research downgraded CareDx from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/15/2025 | $28.00 → $24.00 | Underweight → Equal Weight | Wells Fargo |
| 8/28/2024 | $28.00 | Underweight | Wells Fargo |
| 8/19/2024 | $40.00 | Neutral → Buy | BTIG Research |
| 5/13/2024 | Outperform → Mkt Perform | Raymond James | |
| 5/1/2024 | $15.00 | Hold → Buy | Craig Hallum |
| 11/9/2023 | $10.00 | Equal-Weight → Overweight | Stephens |
| 8/15/2023 | $12.00 | Mkt Perform → Outperform | Raymond James |
| 5/11/2023 | Buy → Neutral | BTIG Research |
Wells Fargo upgraded CareDx from Underweight to Equal Weight and set a new price target of $24.00 from $28.00 previously
Wells Fargo initiated coverage of CareDx with a rating of Underweight and set a new price target of $28.00
BTIG Research upgraded CareDx from Neutral to Buy and set a new price target of $40.00
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
4 - CareDx, Inc. (0001217234) (Issuer)
Board of Directors Authorizes New $50 Million Share Repurchase Program CareDx, Inc. (NASDAQ:CDNA), – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that it has completed the repurchase of $50 million of its common stock representing approximately 5% of outstanding shares. The share repurchase follows the completion of the company's seventh consecutive quarter of testing services volume growth and a first-quarter total revenue of $84.7 million, representing 18% year-over-year growth. CareDx ended
First Quarter Revenue of $84.7 Million, Increased 18% Year-Over-Year Grew Testing Services Volume to Approximately 47,100, Marking Seventh Consecutive Quarter of Sequential Testing Services Volume Growth CareDx, Inc. (NASDAQ:CDNA) today reported financial results for the first quarter ended March 31, 2025. First Quarter Financial Highlights Reported first quarter revenue of $84.7 million, increased 18% year-over-year Testing services revenue of $61.9 million, increased 15% year-over-year, and testing services volume of approximately 47,100, increased 12% year-over-year GAAP net loss of $10.4 million, non-GAAP net income of $5.4 million, and positive adjusted EBITDA of $4.6 million,
CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company™ ("CareDx" or the "Company")— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. Foley's employment with CareDx. CareDx granted Ms. Foley 36,231 restricted stock units ("RSUs") pursuant to the Company's 2016 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Company's Board o